Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3591994 | 1.00 | RAF1 (0.36) | RAF1ALDH1A1SMN1; SMN2TRPV1LMNA | |
| SCHEMBL3588770 | 0.95 | TRPV1 (0.35) | ALDH1A1SMN1; SMN2TRPV1TRPM8 | |
| SCHEMBL3588769 | 0.95 | TRPV1 (0.35) | ALDH1A1SMN1; SMN2TRPV1TRPM8 | |
| SCHEMBL13545481 | 0.88 | RAF1 (0.40) | RAF1TRPV1KCNH2 | |
| SCHEMBL3594179 | 0.87 | TRPV1 (0.42) | ALDH1A1SMN1; SMN2TRPV1 | |
| SCHEMBL3594177 | 0.87 | TRPV1 (0.42) | ALDH1A1SMN1; SMN2TRPV1 | |
| SCHEMBL3594640 | 0.85 | TRPV1 (0.36) | ALDH1A1SMN1; SMN2TRPV1LMNA | |
| SCHEMBL3594637 | 0.85 | TRPV1 (0.36) | ALDH1A1SMN1; SMN2TRPV1LMNA | |
| SCHEMBL3606694 | 0.84 | TRPV1 (0.34) | TRPV1TRPM8 | |
| SCHEMBL3606697 | 0.84 | TRPV1 (0.34) | TRPV1TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | RAF1 1753/4885ALDH1A1 1904/4885SMN1; SMN2 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.